DIN 02539721 — RINVOQ 45 MG
RINVOQ is a tablet (extended-release) of Upadacitinib marketed by ABBVIE CORPORATION. The full Upadacitinib monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02539721
- Brand name
- RINVOQ
- Active ingredient
- Upadacitinib
- Strength
- 45 MG
- Dosage form
- TABLET (EXTENDED-RELEASE)
- Route
- ORAL
- Manufacturer
- ABBVIE CORPORATION
- Health Canada status
- MARKETED
- Drug class
- Janus kinase (JAK) inhibitor (selective immunosuppressant)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Upadacitinib products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02495155 | RINVOQ | 15 MG | TABLET (EXTENDED-RELEASE) | ABBVIE CORPORATION | MARKETED |
| 02520893 | RINVOQ | 30 MG | TABLET (EXTENDED-RELEASE) | ABBVIE CORPORATION | MARKETED |